Drugs / ILB-3101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06426680 | Oct 2024 → Dec 2025 overdue | neoplasm | Innolake Biopharm | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ILB-3101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06426680 ↗ |
| Route | Intravenous | “Intravenous (IV) administration of ILB-3101” NCT06426680 ↗ |